BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28062946)

  • 21. An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease.
    Younossi ZM; Karrar A; Pierobon M; Birerdinc A; Stepanova M; Abdelatif D; Younoszai Z; Jeffers T; Felix S; Jeiran K; Hodge A; Zhou W; Monge F; Alaparthi L; Chandhoke V; Goodman ZD; Petricoin EF
    BMC Med; 2018 Sep; 16(1):170. PubMed ID: 30205811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.
    He K; Zhu X; Liu Y; Miao C; Wang T; Li P; Zhao L; Chen Y; Gong J; Cai C; Li J; Li S; Ruan XZ; Gong J
    Oncotarget; 2017 Jun; 8(23):37657-37672. PubMed ID: 28499273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elovl6 promotes nonalcoholic steatohepatitis.
    Matsuzaka T; Atsumi A; Matsumori R; Nie T; Shinozaki H; Suzuki-Kemuriyama N; Kuba M; Nakagawa Y; Ishii K; Shimada M; Kobayashi K; Yatoh S; Takahashi A; Takekoshi K; Sone H; Yahagi N; Suzuki H; Murata S; Nakamuta M; Yamada N; Shimano H
    Hepatology; 2012 Dec; 56(6):2199-208. PubMed ID: 22753171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice.
    Verbeek J; Spincemaille P; Vanhorebeek I; Van den Berghe G; Vander Elst I; Windmolders P; van Pelt J; van der Merwe S; Bedossa P; Nevens F; Cammue B; Thevissen K; Cassiman D
    Lipids Health Dis; 2017 Feb; 16(1):46. PubMed ID: 28231800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test.
    Korkmaz H; Unler GK; Gokturk HS; Schmidt WE; Kebapcilar L
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1137-43. PubMed ID: 26049707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia.
    Sandoval JC; Nakagawa-Toyama Y; Masuda D; Tochino Y; Nakaoka H; Kawase R; Yuasa-Kawase M; Nakatani K; Inagaki M; Tsubakio-Yamamoto K; Ohama T; Matsuyama A; Nishida M; Ishigami M; Komuro I; Yamashita S
    J Atheroscler Thromb; 2010 Sep; 17(9):914-24. PubMed ID: 20543519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis.
    Bechmann LP; Gieseler RK; Sowa JP; Kahraman A; Erhard J; Wedemeyer I; Emons B; Jochum C; Feldkamp T; Gerken G; Canbay A
    Liver Int; 2010 Jul; 30(6):850-9. PubMed ID: 20408954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced Liver Fibrosis Is Independently Associated with Palmitic Acid and Insulin Levels in Patients with Non-Alcoholic Fatty Liver Disease.
    Cansanção K; Silva Monteiro L; Carvalho Leite N; Dávalos A; Tavares do Carmo MDG; Arantes Ferreira Peres W
    Nutrients; 2018 Oct; 10(11):. PubMed ID: 30380656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absorption and transport of dietary long-chain fatty acids in cirrhosis: a stable-isotope-tracing study.
    Cabré E; Hernández-Pérez JM; Fluvià L; Pastor C; Corominas A; Gassull MA
    Am J Clin Nutr; 2005 Mar; 81(3):692-701. PubMed ID: 15755841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum C16:1n7/C16:0 ratio as a diagnostic marker for non-alcoholic steatohepatitis.
    Yamada K; Mizukoshi E; Seike T; Horii R; Terashima T; Iida N; Kitahara M; Sunagozaka H; Arai K; Yamashita T; Honda M; Takamura T; Harada K; Kaneko S
    J Gastroenterol Hepatol; 2019 Oct; 34(10):1829-1835. PubMed ID: 30864239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased duodenal iron absorption through up-regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis.
    Hoki T; Miyanishi K; Tanaka S; Takada K; Kawano Y; Sakurada A; Sato M; Kubo T; Sato T; Sato Y; Takimoto R; Kobune M; Kato J
    Hepatology; 2015 Sep; 62(3):751-61. PubMed ID: 25753988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The unity of pathogenesis of insulin resistance syndrome and non-alcoholic fatty disease of liver. The metabolic disorder of fatty acids and triglycerides].
    Titov VN; Ivanova KV; Malyshev PP; Kaba SI; Shiriaeva IuK
    Klin Lab Diagn; 2012 Nov; (11):3-12. PubMed ID: 23305008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between insulin resistance and liver histology in patients with nonalcoholic steatohepatitis with and without obesity.
    Lazar MV; Eapen M; Nair HR; Siyad I; Gopalakrishna R
    Indian J Gastroenterol; 2020 Feb; 39(1):42-49. PubMed ID: 32222944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous MR quantification of hepatic fat content, fatty acid composition, transverse relaxation time and magnetic susceptibility for the diagnosis of non-alcoholic steatohepatitis.
    Leporq B; Lambert SA; Ronot M; Vilgrain V; Van Beers BE
    NMR Biomed; 2017 Oct; 30(10):. PubMed ID: 28678410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology.
    Jung KY; Cho SY; Kim HJ; Kim SB; Song IH
    J Clin Gastroenterol; 2014; 48(10):883-8. PubMed ID: 24440936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MTTP-297H polymorphism reduced serum cholesterol but increased risk of non-alcoholic fatty liver disease-a cross-sectional study.
    Hsiao PJ; Lee MY; Wang YT; Jiang HJ; Lin PC; Yang YH; Kuo KK
    BMC Med Genet; 2015 Oct; 16():93. PubMed ID: 26458397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered fatty acid metabolism-related gene expression in liver from morbidly obese women with non-alcoholic fatty liver disease.
    Auguet T; Berlanga A; Guiu-Jurado E; Martinez S; Porras JA; Aragonès G; Sabench F; Hernandez M; Aguilar C; Sirvent JJ; Del Castillo D; Richart C
    Int J Mol Sci; 2014 Dec; 15(12):22173-87. PubMed ID: 25474087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.